Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

BERLIN ― Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products such as breast cancer drug Kisqali during the second quarter.

Oil prices rose on Thursday as analysts pointed to low inventories and renewed Middle East risks as factors supporting the ...

The Senate has passed about $9 billion in federal spending cuts requested by President Donald Trump, including deep ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

In the midst of climate change, awareness of humanity’s negative impact on the planet has grown, making the idea of moving to another planet more appealing. This led to the concept of Biosphere 2, ...